Adial Pharmaceuticals
ADIL
12 hedge funds and large institutions have $151K invested in Adial Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0.04% less ownership
Funds ownership: 0.18% → 0.14% (-0.04%)
8% less funds holding
Funds holding: 13 → 12 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
49% less capital invested
Capital invested by funds: $296K → $151K (-$145K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$22.1K |
| 2 |
VF
Virtu Financial
New York
|
+$21.8K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.78K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$640 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$55.1K |
| 2 |
Renaissance Technologies
New York
|
-$48.1K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$27K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $43.7K | +$5.78K | +280 | +11% |
|
|
MCM
2
Manchester Capital Management
Manchester,
Vermont
| $30.5K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $30.3K | +$22.1K | +1,069 | +127% |
|
4
BlackRock
New York
| $17.6K | – | – | – |
|
|
VF
5
Virtu Financial
New York
| $17K | +$21.8K | +1,057 | New |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $8.34K | +$10.9K | +526 | New |
|
|
1IA
7
1620 Investment Advisors
Plymouth,
Massachusetts
| $2.28K | – | – | – |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $905 | +$640 | +31 | +119% |
|
|
SS
9
SBI Securities
Tokyo,
Japan
| $588 | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $101 | – | – | – |
|
11
Bank of America
Charlotte,
North Carolina
| $35 | – | – | – |
|
|
AWM
12
Abound Wealth Management
Franklin,
Tennessee
| $18 | – | – | – |
|
13
Morgan Stanley
New York
| $6 | – | – | – |
|
|
14
Citadel Advisors
Miami,
Florida
| – | -$55.1K | -2,180 | Closed |
|
|
15
Renaissance Technologies
New York
| – | -$48.1K | -1,905 | Closed |
|
|
16
Cambridge Investment Research Advisors
Fairfield,
Iowa
| – | -$27K | -1,080 | Closed |
|
ADIL Hedge Fund Activity: Q1 2025 in Review
12 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q1 2025, worth a combined $151K — down 49% from $296K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ADIL and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.
The largest buyer was UBS Group, adding an estimated $22.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $55.1K sold.
- 12 institutional investors held Adial Pharmaceuticals (ADIL) as of Q1 2025, down from 13 in Q4 2024.
- Funds reported $151K of Adial Pharmaceuticals stock for Q1 2025, down 49% quarter-over-quarter.
- 2 funds opened new Adial Pharmaceuticals positions in Q1 2025 and 3 closed out, a net change of -1 holder.
- The largest Adial Pharmaceuticals buyer in Q1 2025 was UBS Group, an estimated $22.1K added.
- The largest Adial Pharmaceuticals seller in Q1 2025 was Citadel Advisors, an estimated $55.1K sold.
Based on aggregated 13F filings for Q1 2025.